APA (7th ed.) Citation

Caffo, O., Frantellizzi, V., Tucci, M., Galli, L., Monari, F., Baldari, S., . . . Cortesi, E. (2020). Fracture risk and survival outcomes in metastatic castration-resistant prostate cancer patients sequentially treated with abiraterone acetate and RADIUM-223. European Journal of Nuclear Medicine & Molecular Imaging, 47(11), 2633. https://doi.org/10.1007/s00259-020-04796-w

Chicago Style (17th ed.) Citation

Caffo, Orazio, et al. "Fracture Risk and Survival Outcomes in Metastatic Castration-resistant Prostate Cancer Patients Sequentially Treated with Abiraterone Acetate and RADIUM-223." European Journal of Nuclear Medicine & Molecular Imaging 47, no. 11 (2020): 2633. https://doi.org/10.1007/s00259-020-04796-w.

MLA (9th ed.) Citation

Caffo, Orazio, et al. "Fracture Risk and Survival Outcomes in Metastatic Castration-resistant Prostate Cancer Patients Sequentially Treated with Abiraterone Acetate and RADIUM-223." European Journal of Nuclear Medicine & Molecular Imaging, vol. 47, no. 11, 2020, p. 2633, https://doi.org/10.1007/s00259-020-04796-w.